ATE466879T1 - 5t4-antigen-peptidepitope der mhc klasse ii - Google Patents

5t4-antigen-peptidepitope der mhc klasse ii

Info

Publication number
ATE466879T1
ATE466879T1 AT03739570T AT03739570T ATE466879T1 AT E466879 T1 ATE466879 T1 AT E466879T1 AT 03739570 T AT03739570 T AT 03739570T AT 03739570 T AT03739570 T AT 03739570T AT E466879 T1 ATE466879 T1 AT E466879T1
Authority
AT
Austria
Prior art keywords
mhc class
antigen peptide
peptide epitopes
epitope
peptide
Prior art date
Application number
AT03739570T
Other languages
English (en)
Inventor
Miles Carroll
Richard Harrop
Susan Kingsman
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of ATE466879T1 publication Critical patent/ATE466879T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03739570T 2002-02-13 2003-02-13 5t4-antigen-peptidepitope der mhc klasse ii ATE466879T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0203420.5A GB0203420D0 (en) 2002-02-13 2002-02-13 Peptide
PCT/GB2003/000618 WO2003068815A2 (en) 2002-02-13 2003-02-13 Mhc class ii peptide epitope of 5t4 antigen

Publications (1)

Publication Number Publication Date
ATE466879T1 true ATE466879T1 (de) 2010-05-15

Family

ID=9931005

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03739570T ATE466879T1 (de) 2002-02-13 2003-02-13 5t4-antigen-peptidepitope der mhc klasse ii

Country Status (7)

Country Link
US (2) US7910109B2 (de)
EP (1) EP1474446B1 (de)
AT (1) ATE466879T1 (de)
AU (1) AU2003245781A1 (de)
DE (1) DE60332425D1 (de)
GB (1) GB0203420D0 (de)
WO (1) WO2003068815A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606287A1 (en) 2005-05-13 2006-11-16 Oxford Biomedica (Uk) Limited Peptide
GB0520067D0 (en) * 2005-10-01 2005-11-09 Cancer Rec Tech Ltd Treatment of cancer
US8642274B2 (en) * 2008-07-15 2014-02-04 Oxford Biomedica, Inc. Immunotherapeutic method
US9290541B2 (en) 2011-11-18 2016-03-22 Board Of Regents, The University Of Texas System TCL1 peptides for immunotherapy
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201607535D0 (en) * 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
CA3007301A1 (en) 2015-12-04 2017-06-08 Board Of Regents, The University Of Texas System Slc45a2 peptides for immunotherapy
JP2020503840A (ja) 2016-10-07 2020-02-06 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｈｌａ拘束性ｖｇｌｌ１ペプチドおよびその使用
WO2018126002A1 (en) * 2016-12-29 2018-07-05 Board Of Regents, The University Of Texas System Hla-restricted vcx/y peptides and t cell receptors and use thereof
JP2021500878A (ja) 2017-10-12 2021-01-14 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫療法のためのｔ細胞受容体
WO2019139972A1 (en) 2018-01-09 2019-07-18 Board Of Regents, The University Of Texas System T cell receptors for immunotherapy
AU2021275239A1 (en) 2020-05-21 2022-12-15 Board Of Regents, The University Of Texas System T cell receptors with VGLL1 specificity and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570940B2 (en) 1982-11-30 1988-03-31 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Process for producing poxvirus recombinants for expression offoreign genes
GB8305967D0 (en) 1983-03-04 1983-04-07 Univ Liverpool Material for treatment of spontaneous abortions
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5869053A (en) 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
EP0403559A1 (de) 1988-03-04 1990-12-27 Cancer Research Campaign Technology Limited Antigene
US5118672A (en) 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
IL92629A0 (en) 1989-12-10 1990-08-31 Yeda Res & Dev Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
GB9523703D0 (en) 1995-11-20 1996-01-24 Wellcome Found Enzyme prodrug thearapy
US5864003A (en) 1996-07-23 1999-01-26 Georgia-Pacific Resins, Inc. Thermosetting phenolic resin composition
KR20010052076A (ko) 1997-09-23 2001-06-25 찰스 굿맨 허혈 조건에서 헤마토포이에틱 스템 세포의 유전자 발현
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
GB2370571B (en) 1998-11-18 2003-05-07 Oxford Biomedica Ltd A modified 5t4 antigen
EP1036091B2 (de) * 1998-11-18 2008-03-26 Oxford Biomedica (UK) Limited Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
ATE512666T1 (de) 1999-06-29 2011-07-15 Epimmune Inc Hla-bindende peptide und ihre verwendungen

Also Published As

Publication number Publication date
US20050118597A1 (en) 2005-06-02
US7910109B2 (en) 2011-03-22
EP1474446B1 (de) 2010-05-05
AU2003245781A1 (en) 2003-09-04
EP1474446A2 (de) 2004-11-10
WO2003068815A2 (en) 2003-08-21
US20130217116A1 (en) 2013-08-22
WO2003068815A3 (en) 2003-09-18
GB0203420D0 (en) 2002-04-03
DE60332425D1 (de) 2010-06-17
AU2003245781A8 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
TW200602071A (en) Methods for preventing and treating alzheimer's disease (ad)
ATE466879T1 (de) 5t4-antigen-peptidepitope der mhc klasse ii
ATE376559T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
NO20045021L (no) Immunologiske metoder og preparater for behandling av Alzheimers sykdom
NO20022531L (no) Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
EP2258383A3 (de) Von der Telomerase abgeleitete antigene Peptide
DE69526339D1 (de) Monoklonale antikörper, die an den vorläufer des tumorabstossantigen mage-1 anbinden, rekombinantes mage-1, und von mage-1 abgebieteteimmunogene peptide
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
RU2008120299A (ru) СПОСОБЫ ПОЛУЧЕНИЯ КОМПОЗИЦИЙ, ВКЛЮЧАЮЩИХ ХИТШОКОВЫЕ БЕЛКИ ИЛИ α-2-МАКРОГЛОБУЛИН, ПРИГОДНЫХ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ И ИНФЕКЦИОННОГО ЗАБОЛЕВАНИЯ
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
DE60035523D1 (de) Optimierte minigene und dadurch kodierte peptide
ATE360642T1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4
PT1417222E (pt) Polipéptidos isolados baseados no epítopo neutralizante da proteína p17 de vih, úteis como vacinas, e anticorpos antip17 neutralizantes que reconhecem especificamente o referido polipéptido neutralizante
ATE356140T1 (de) Gd3 mimetische peptide
NZ592340A (en) A method for making a virus vaccine compising Replikin peptides
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
ATE248601T1 (de) Impfstoff gegen rotavirus infektionen enthaltend peptide des viralenterotoxines nsp4
UA83989C2 (ru) Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение
EP1557466A4 (de) Tumorantigenprotein und dessen verwendung
DE602004019141D1 (de) Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonin (ivtntt) enthaltende biologisch wirksame peptide
AR051853A1 (es) Vacuna para aumentar el crecimiento basada en epitopes neutralizantes
DK1778271T3 (da) Peptid til behandling af herpesvirusinfektioner
DE60015559D1 (de) Sentrin-spezifische menschliche protease senp1
WO2003064446A3 (en) Plasma protein-binding peptides from bacterial curli
FR2856598A1 (fr) Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties